ACEI/CCB Versus ACEI/DIU Combination Antihypertensive Therapy in Chinese Hypertensive Patients (ACvAD)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 560 participants.
Also called NCT03682692
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 560 participants
- Registry
-
NCT03682692
-
- Other papers using this trial's data
- Antihypertensive treatment effect of two dual therapies according to sodium sensitivity
- Comparison of two single-pill dual combination antihypertensive therapies in Chinese patients: a randomized, controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03682692. Randomized; single masking; primary purpose treatment. Start 2018-06-01 (actual); primary completion 2021-06-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ACEI/CCB Versus ACEI/DIU Combination Antihypertensive Therapy in Chinese Hypertensive Patients (ACvAD)
- Condition
- Hypertension
- Intervention (Drug)
- ACEI/CCB
- Intervention (Drug)
- ACEI/DIU
- Lead sponsor
- Shanghai Jiao Tong University School of Medicine
Record details
- Record id
cardio:ct-nct03682692- Content hash
7b22d71dad53aabfd502e0bbc210afab1ec2b9afc2dc1051a3f839343567be76